Lifeline Biotechnologies, Inc. Prepares an FDA Filing

RENO, Nev.--(Business Wire)--
Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) today announced that
management is preparing for a filing with the FDA for the Company`s First
Warning System, a capable process designed to assist in the early detection of
breast cancer.

Jim Holmes, CEO of Lifeline, said that its "subsidiary, First Warning Systems,
Inc., is focused on preparing a preliminary filing with the FDA. The FDA`s
response to this initial filing could take several months to receive. We expect
the FDA`s response to give us guidance for the subsequent filing required in
order to obtain marketing clearance for this proprietary process."

Lifeline Biotechnologies has in the past year filed for a patent on the recent
technological advancements of the First Warning System, which has achieved the
robust capability of identifying and classifying tissue abnormalities of the
breast with sensitivities (ability to identify) of 95% to 100% and specificities
(verify) of 87% to 90%. Currently, it is a well known fact that mammograms are
missing an estimated 20% to 30% of the breast cancers.

Holmes noted that "Brass Bulls, an investor relations firm previously assisting
the Company, will no longer be used as their consulting agreement has expired.
The Company`s website has been updated and our direct phone number has been
included thereon."

Safe Harbor: This release includes forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 27E of the Securities
Act of 1934. Statements contained in this release that are not historical facts
may be deemed to be forward-looking statements. Investors are cautioned that
forward-looking statements are inherently uncertain. Actual performance and
results may differ materially from that projected or suggested herein due to
certain risks and uncertainties including, without limitation, ability to obtain
financing, successful development of the Company`s product and regulatory and
shareholder approval for anticipated actions.

Investor Relations
Lifeline Biotechnologies, Inc.
Jim Holmes, 775-324-1933

Copyright Business Wire 2009